How bevacizumab affects gum and mouth healing after tooth extraction in cancer patients in central Algeria

The impact of bevacizumab on mucosal healing after dental extraction in patients undergoing cancer treatment in the central region of Algeria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN50841639

Enrollment

Registered

2026-07-31

Start date

2019-06-07

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer or malignant tumors requiring tooth extraction in patients undergoing antineoplastic treatments (bevacizumab and/or conventional chemotherapy). Cancer

Interventions

This study is a comparative, prospective, multicenter interventional study. Baseline data were collected at the time of inclusion (before dental extraction and before any intervention), including demo

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years of age 2. Patients receiving bevacizumab as monotherapy or in combination with conventional chemotherapy 3. Patients treated solely with conventional chemotherapy 4. Patients presenting an indication for tooth extraction 5. Patients with a recent biological assessment (Complete Blood Count) allowing safe tooth extraction, with neutrophils greater than or equal to 1500/mm³ and platelets greater than or equal to 50,000/mm³ 6. Patients who have provided informed consent

Exclusion criteria

Exclusion criteria: 1. Patients on antiangiogenic treatments other than bevacizumab 2. Patients treated with or scheduled to receive bisphosphonates within three months following the extraction 3. Patients taking anticoagulants or non-steroidal anti-inflammatory drugs (NSAIDs) 4. Uncontrolled diabetes 5. Renal or hepatic insufficiency 6. Unstable cardiac conditions 7. Autoimmune diseases 8. Hemostasis disorders 9. Previous or planned head and neck radiotherapy within three months following the extraction 10. Psychiatric disorders 11. Difficult tooth extractions requiring alveolectomy 12. Acute oral infection 13. Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Delayed mucosal healing measured using a clinical assessment of the persistence of pain with a 10-point Visual Analog Scale (VAS), infection, edema, exposed alveolar bone, or lack of epithelialization/mucosal coverage, at 1 month (30 days) post-extraction	—

Countries

Algeria

Contacts

Public ContactHanane Ammar Boudjelal

ammar_hanane@univ-blida.dz+213 0550616424

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 25, 2026